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Medulloblastoma is a malignant childhood cerebellar tumour type that comprises distinct molecular subgroups. Whereas genomic characteristics of these subgroups are well defined, the extent to which cellular diversity underlies their divergent biology and clinical behaviour remains largely unexplored. Here we used single-cell transcriptomics to investigate intraand intertumoral heterogeneity in 25 medulloblastomas spanning all molecular subgroups. WNT, SHH and Group 3 tumours comprised subgroup-specific undifferentiated and differentiated neuronal-like malignant populations, whereas Group 4 tumours consisted exclusively of differentiated neuronal-like neoplastic cells. SHH tumours closely resembled granule neurons of varying differentiation states that correlated with patient age. Group 3 and Group 4 tumours exhibited a developmental trajectory from primitive progenitor-like to more mature neuronal-like cells, the relative proportions of which distinguished these subgroups. Cross-species transcriptomics defined distinct glutamatergic populations as putative cells-of-origin for SHH and Group 4 subtypes. Collectively, these data provide insights into the cellular and developmental states underlying subtype-specific medulloblastoma biology.
Medulloblastoma (MB) comprises a series of molecularly and clinically diverse malignant childhood cerebellar tumours 1 . While advances in treatment have improved survival, many patients suffer from neurological sequelae or still succumb to their disease. Genomic studies of bulk patient cohorts have defined four consensus molecular subgroups (WNT, SHH, Group 3 and Group 4) 2 , each characterized by discrete genomic landscapes, patient demographics and clinical phenotypes [3] [4] [5] [6] [7] . The association between genotypes, transcriptional profiles, and patient age at diagnosis suggests that distinct MB subgroups arise from the transformation of different cell types in precise spatiotemporal patterns. Such genotype-to-cell-type associations have been partially investigated for WNT and SHH MBs, which are thought to originate from cells in the extracerebellar lower rhombic lip 8 and from cerebellar granule neuron progenitors (GNPs) 9, 10 , respectively. By contrast, cellular origins of Group 3 and Group 4 MB remain unconfirmed. Overlapping transcriptional and epigenetic signatures observed in bulk profiling studies have consistently hampered definitive classification of Group 3 and Group 4 tumours and suggest that they may share common developmental origins 3, 11 . Thus, a better understanding of MB cellular composition and substructure according to subgroup is a critical goal, especially for the poorly characterized Group 3 and Group 4.
Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful method to comprehensively characterize cellular states in healthy and diseased tissues 12 . Whereas in central nervous system malignancies, scRNA-seq has been applied to decipher adult and paediatric gliomas [13] [14] [15] [16] , such approaches have yet to be deployed across MB subgroups. Here we applied full-length scRNA-seq across consensus MB subgroups to infer cellular trajectories, deconvolute bulk MB expression cohorts and nominate developmental origins. We find that WNT, SHH and Group 3 tumours exhibit subgroup-specific cellular trajectories that consist of malignant undifferentiated and differentiated neuronal-like populations, whereas Group 4 tumours recapitulate more differentiated populations of known lineage. Collectively, these data provide insights into the molecular and cellular architecture of MB Article reSeArcH across all subgroups, with the potential to inform future studies aimed at improving patient outcomes.
MB and cerebellar transcriptomes
We prospectively obtained fresh surgical resections from 25 patients with MB (23 diagnostic samples and 2 recurrences) and 11 patient-derived xenograft (PDX) models ( Table 1a ). Each tumour sample was classified on a molecular level using DNA methylation arrays 17 ( Fig. 1b,  Extended Data Fig. 1b) . The majority of tumours were also characterized by whole-genome (n = 5) or whole-exome (n = 12) sequencing (Fig. 1b, Supplementary Table 1b) . To perform full-length scRNA-seq, cells were dissociated, sorted for viability and profiled using the Smart-seq2 protocol 18 (see Methods). Analysis of known subgroupspecific signature genes 19 demonstrated expected expression patterns (Extended Data Fig. 1b, c) . Pairwise correlation of aggregated scR-NA-seq and DNA methylation array data further substantiated subgroup classifications and PDX model fidelity (Extended Data Fig. 1d ). Scoring single cells using published transcriptional signatures revealed that WNT and SHH tumours consist exclusively of cells scoring highly for their respective signatures. Conversely, cells derived from Group 3 and Group 4 tumours exhibited some degree of transcriptional overlap (Extended Data Fig. 1e ). In total, 8,734 single cells passed quality control, with a median of 4,561 genes detected per cell (Supplementary  Table 1a) .
To classify single cells into malignant and non-malignant subsets, we used two complementary strategies. First, we inferred genomewide copy-number variations (CNVs) from the scRNA-seq data as previously described 13 (see Methods). This analysis identified largescale genomic gains and losses in most (21 out of 25) patient samples, including hallmark alterations such as monosomy 6 (WNT) and isochromosome 17q (Groups 3 and 4; Extended Data Fig. 2a-e) . Few cells (n = 36) from these patients lacked discernable CNVs (see Methods). Second, we clustered single cells across all samples according to their transcriptional profiles. A minority of single cells in our cohort clustered with reference immune cells (n = 6) or oligodendrocytes (n = 22) (Extended Data Fig. 3a, b) . All cells that lacked CNVs and/or clustered with normal reference populations were deemed as non-malignant and excluded from further analysis (n = 43). Across individual tumours, 96-100% of cells were classified as malignant, consistent with previous estimates of high MB tumour cell fractions based on genome sequencing 20 . We further validated these assignments by quantifying genetic mutations identified by bulk tumour DNA sequencing in our scR-NA-seq data (1,937 mutant and 1,952 wild-type transcripts detected; see Methods, Extended Data Fig. 3c-f) .
To relate MB single-cell profiles to normal developmental hierarchies, we leveraged recently generated scRNA-seq data for mouse cerebellar development spanning 13 embryonic and early postnatal time points 21 (total of 78,156 single cells; Fig. 1a , c, Extended Data Fig. 4a -e, Supplementary Table 1c) . Canonical correlation analysis (CCA; see Methods) facilitated cross-species comparisons between our mouse cerebellar single-cell, human MB single-cell and bulk 3 expression datasets. SHH MB was highly correlated with GNP populations (cosine distance = 0.54), consistent with literature 9, 10 , supporting GNPs as the cell-of-origin for this subgroup (Fig. 1d, Extended  Data Fig. 4f) . Notably, Group 4 MB was highly correlated with unipolar brush cells (UBC; cosine distance = 0.50) and glutamatergic cerebellar nuclei (GluCN; cosine distance = 0.49). By contrast, we did not detect high-confidence correlations between any cerebellar populations and either WNT or Group 3 subgroups.
Malignant trajectories within WNT MB
Children with WNT MB account for about 10% of patients with MB and have an excellent prognosis 22 . Somatic CTNNB1 mutations or germline APC mutations, both of which drive constitutive WNT signalling, are found in nearly all WNT MBs 3, 23 . Five WNT tumours were included in our dataset. Pairwise correlation analysis revealed multiple distinct transcriptional states that were consistently identified within these tumours (Fig. 2a) . Inferring CNVs from our scRNA-seq data identified four cases with monosomy 6, a stereotypic genomic feature of this subgroup (Fig. 2b, Extended Data Fig. 2a ). The fifth case (BCH807) exhibited chromosome 19 gain and was negative for nuclear β-catenin by immunohistochemistry (data not shown), both of which are atypical characteristics for this subgroup despite high-confidence molecular classification as WNT MB (Fig. 1b) . SJ99 exhibited marked heterogeneity at both a transcriptional and genetic level, with evidence for two distinct subclones. Subclone SJ99-A exhibited monosomy 6 and chromosome 17p loss, whereas subclone SJ99-B exhibited broad gains and losses affecting nearly every chromosome. Investigation of genetically supported single-nucleotide variants (SNVs) confirmed expression of mutant transcripts in 57.2% of cells (including key WNT MB driver genes CTNNB1, DDX3X and TP53; Fig. 2c ).
Non-negative matrix factorization (NMF) was applied to define underlying transcriptional programs specific to each tumour (Extended Data Fig. 5a , b, Supplementary Table 2a, see Methods). This analysis revealed highly similar programs in all five WNT MBs, which we grouped accordingly into four metaprograms (WNT-A, WNT-B, WNT-C and WNT-D). To interpret the characteristics of each metaprogram, we evaluated their underlying gene signatures. WNT-A contained numerous markers of cell cycle activity (such as TOP2A, CDK1 SJ516  MUV44  BCH807   SJ99  SJ129  SJ577  SJ454  MUV41  SJ625  MUV11  SJ17  SJ917  SJ617  MUV29*  BCH1205  MUV34  BCH825  MUV39  SJ723  SJ217  MUV27  BCH1031  MUV19  MUV37 Article reSeArcH and RRM2; P < 0.001, Fisher's exact test; Supplementary Table 2b) . WNT-C was characterized by markers of neurogenesis or neuronal differentiation (such as STMN2, KIF5C and SYT11; P < 0.001; Fig. 2d ). WNT-B consisted of ribosomal and metabolic genes (NME2, HK2 and PGM5), and WNT-D contained select WNT-pathway genes (LRP4 and APCDD1) and immediate early response genes (JUNB and EGR1; Fig. 2d ). Cells scoring highest for both WNT-B and WNT-D expressed elevated levels of additional canonical WNT pathway genes (DKK2, AXIN2 and WIF1) and MYC (Extended Data Fig. 5c , Supplementary  Table 2c ). We interpret these metaprograms as reflecting cell cycle activity (WNT-A), neuronal-like differentiation (WNT-C) and two WNT-driven states (WNT-B and WNT-D), with WNT-B characterized by elevated protein biosynthesis and metabolism (Fig. 2d) . RNA in situ hybridization performed on the same tumours validated the expression of specific metaprogram marker genes in subpopulations of cells (Extended Data Fig. 5d ). Moreover, scoring each cell in our cohort for these four metaprograms defined a putative developmental trajectory for WNT MB, with cell cycle activity restricted to cells that were both high in WNT-B and low in WNT-C and WNT-D (Fisher's exact test, P < 0.001), suggesting that this subpopulation fuels WNT MB growth (Fig. 2e) . Notably, each metaprogram was identified in at least four samples (Extended Data Fig. 5a ), suggesting that the programs reflect shared features of WNT MB.
Developmental trajectories within SHH MB
As the dominant subgroup in both infants (≤3 years old) and adults (≥18 years old) 22 , SHH MB accounts for about one third of all patients with MB. Outcomes are heterogeneous and associated with underlying genetics, demographics and clinical features 24 . Our dataset included three patients with SHH MB, ranging in age from 3 to 13 years (Fig. 1b) . Pairwise correlation and unsupervised NMF analysis revealed three transcriptional programs (SHH-A, -B and -C) shared among these tumours (Fig. 3a, Extended Data Fig. 6a, b, Supplementary Table 2a, b) . SHH-A contained markers of cell cycle activity (for example, TOP2A, CDK1 and RRM2; P < 0.001, Fisher's exact test). SHH-B was enriched for ribosomal genes and translational initiation and elongation factors (EIF3E and EEF1A1; P < 0.001), and markers of canonical SHH signalling (PTCH1 and BOC; P < 0.001; Fig. 3b ). SHH-C was defined by markers of neuronal differentiation (STMN2, MAP1B, TUBB2B and SEMA6A; P < 0.001; Fig. 3b ). We interpret these programs as reflecting cell cycle activity (SHH-A), undifferentiated progenitors (SHH-B) and more differentiated neuronal-like programs (SHH-C). Scoring each SHH MB cell for these programs defined a putative developmental trajectory, with proliferating cells restricted to undifferentiated progenitors (Fig. 3c) . These respective programs were partially recapitulated in SHH subgroup PDX models (Extended Data Fig. 6c, d) .
To investigate the developmental significance of these findings, we used CCA to compare SHH MB metaprograms to mouse cerebellar populations. SHH-B correlated with undifferentiated UBC-GNP and GNP populations, whereas SHH-C correlated with UBC-GN intermediate and differentiated granule neuron populations (Fig. 3d , Extended Data Fig. 7a-d) . To validate these observations in a larger cohort, we implemented a focused analysis of UBC, GNP and granule neuron populations, assessing correlations between these cell types and bulk SHH MB expression profiles (Fig. 3e, Extended Data  Fig. 7e ). This analysis broadly split SHH MBs into two age-associated categories: infant tumours correlated with intermediate and mature granule neurons (marked by high expression of NEUROD1), whereas adult tumours correlated with GNPs and mixed UBC and GN progenitors (marked by high expression of ATOH1; Fig. 3e , f, Extended Data Fig. 7f-j) . Together, our data suggest that infant and adult SHH MBs are enriched for temporally distinct GNP (or UBC) populations and/or have distinct differentiation capacities, further supporting their divergent biology [25] [26] [27] .
Malignant programs within Group 3/4 MB
Group 3 and Group 4 tumours account for about 60% of MB diagnoses and remain the least understood with respect to disease biology and developmental origins 7 . Group 3 tumours are frequently metastatic at diagnosis and are typified by genomic amplification or overexpression 
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of MYC, which is associated with unfavourable outcomes 11, 28 . Group 4 tumours are metastatic at diagnosis in approximately one third of patients and harbour recurrent chromatin modifier alterations 28, 29 . Recent bulk-profiling studies have demonstrated marked molecular and clinical heterogeneity in Group 3 and Group 4, with a subset of tumours exhibiting overlapping molecular signatures that confound robust classification 3, 30, 31 . On the basis of this prior knowledge, we performed a combined analysis of the scRNA-seq data for all 17 The observation that Group 3 and Group 4 MBs both contained cells scoring high for the neuronal-like differentiation program (Group 3/4-C) prompted us to examine whether varying proportions of cells with this shared program could underlie the molecular overlap seen in bulk tumour profiles. Quantifying the Group 3/4-B and C programs in bulk MB gene expression data 3 (n = 248 Group 3/4 MBs) recapitulated observations made in our single-cell cohort (Fig. 5a ). Sorting these profiles by their relative scores for these programs confirmed that prototypic Group 3 MBs were largely characterized by the undifferentiated progenitor-like program (Group 3/4-B), whereas prototypic Group 4 MBs were dominated by the differentiated neuronal-like program (Group 3/4-C). A considerable fraction of tumours (19.8%) exhibited evidence of both programs (Fig. 5a, Extended Data Fig. 9a ). These intermediate tumours were characterized by elevated DNA methylation-based prediction scores (≥0.2) for both subgroups (odds ratio = 8.9, P < 0.001, Fisher's exact test). We validated these results by SJ970  MUV37  MUV19  BCH1031  MUV27  SJ217  SJ723  MUV39  SJ625  BCH825  MUV34  BCH1205  MUV29  SJ617  SJ917  SJ17  MUV11   NM   SJ970  MUV37  MUV19   BCH1031   MUV27   SJ217  SJ723  MUV39   SJ625   BCH825   MUV34   BCH1205   MUV29   SJ617   SJ917   SJ17   MUV11 We next investigated whether recently described 3,32 DNA methylation-based subtypes of Group 3/4 MB were related to the metaprograms inferred from scRNA-seq. We found that DNA methylation subtypes I and V, both of which contain a mixture of Group 3 and Group 4 MBs, were significantly enriched for tumours with intermediate expression patterns (P < 0.001, Fisher's exact test; Fig. 5c, Extended Data Fig. 9c ). These results suggest that a continuum of cellular states accounts for the molecular substructure seen in Group 3/4 that complicates accurate consensus classification.
Lineage-specific correlates of Group 4 MB
We next sought to compare and interrelate the different subgroup-specific metaprograms. To this effect, we applied all observed metaprograms (n = 10) to all 7,745 malignant cells in our dataset. Pairwise correlation of expression scores confirmed high similarity among cell cycle programs (WNT-A, SHH-A, Group 3/4-A; average r = 0.99) (Fig. 6a) . The undifferentiated progenitor-like programs (WNT-B, SHH-B and Group 3/4-B) exhibited low correlations (average r = 0.23), in agreement with their distinct underlying biology. By contrast, the neuronal-like differentiation programs (WNT-C, SHH-C and Group 3/4-C) were highly correlated (average r = 0.77; Fig. 6a , b, Extended Data Fig. 9d ), consistent with shared capacity for neuronal differentiation across subgroups. We reasoned that the neuronal-like differentiation programs defined in each subgroup consist of general neuronal differentiation markers, potentially masking markers of specific lineages. To elucidate markers that might inform developmental origins, we compared genes specific to neuronal-like cells in the different subgroups (n = 260; relative to undifferentiated cell populations; see Methods). Half of these genes (52%) were shared between at least two subgroups and included general markers of neuronal differentiation (for example, ENO2, SYT11, TUBB3 and MAP2), while the remainder were exclusive to individual subgroups (13-20%; Fig. 6c , Extended Data Fig. 9e, Supplementary Table 3 ). Glutamatergic lineage-specific transcription factors EOMES and LMX1A ranked among the most-differentially expressed genes specific to the Group 3/4-C program (Fig. 6c, Supplementary Table 3 ). In mice, these transcription factors have essential roles in defining neuronal cell fates in the embryonic upper rhombic lip (uRL), including UBCs and GluCN, both of which are born out of the uRL during cerebellar morphogenesis 33, 34 . As our earlier CCA analysis identified both UBCs and GluCN as being highly correlated with Group 4 MB expression datasets (Fig. 1d, Extended Data Fig. 4f ), we performed a deeper analysis into these correlations. Discriminatory UBC markers were specifically expressed in Group 4 single cells and bulk tumour profiles, implicating a possible developmental link between UBCs and Group 4 MB (Fig. 6d , e, Extended Data Fig. 9f ). Similar results were observed for GluCN, although the highest correlations were limited to a subset of Group 4 tumours (Extended Data Fig. 10a-f) . Collectively, these associations further implicate UBCs and GluCN of the embryonic cerebellum as candidate cells-of-origin for Group 4 MB.
Discussion
Despite extensive characterization of MB genomic landscapes, effective subgroup-specific therapies have yet to emerge, suggesting that a deeper understanding of the biological and cellular basis of MB is essential. This is particularly urgent for Group 3 and Group 4 MB, which often bear inferior outcomes. As a first challenge, these subgroups have proven difficult to accurately classify, confounded by transcriptional and epigenetic ambiguity. Our combined single-cell analysis of Group 3/4 MBs confirmed that prototypic Group 3 MBs are dominated by undifferentiated progenitor-like cells, whereas prototypic Group 4 MBs consist almost exclusively of more differentiated neuronal-like cells. Of note, we identified a subset of intermediate tumours characterized by varying proportions of both undifferentiated and more differentiated populations (Extended Data Fig. 10g ). These findings offer a novel molecular and cellular explanation for the challenges associated with Group 3 and Group 4 sub-classification and provide a framework for future classifications that incorporate population heterogeneity. Cellular origins for WNT and SHH MB have been mostly informed from genetically faithful mouse models 8, 9 . Cross-species transcriptional analyses performed here confirmed significant correlations between SHH MB and GNPs of variable differentiation states that were associated with patient age. Moreover, our analyses identified UBCs and GluCN as cellular correlates of Group 4 MB subtypes, building on previous studies that have implicated glutamatergic cellular origins for Group 4 4 . For WNT MB, we failed to identify significant correlation between malignant single-cell programs and cerebellar populations, consistent with an extracerebellar origin for this subgroup 8 . No significant correlations were detected between Group 3 MB and our cerebellar dataset. This observation may be attributed to transformation and cellular reprogramming driven by specific oncogenes (that is, MYC) or may imply that Group 3 MBs have an extracerebellar origin. It is also plausible that our mouse reference atlas was incomplete and lacked populations pertinent to either WNT or Group 3 MB origins. Technical limitations of comparing single-cell datasets between species should not be underestimated, warranting future studies of the cellular correlates between human cerebellar and MB single cells.
In conclusion, our work provides a cellular atlas of MB across all subgroups and a cross-species comparison of cerebellar development, TUJ1   MYC   SJ787  SJ427  SJ551  SJ666  SJ893  SJ589  SJ599  SJ15  SJ492  SJ95  SJ350  SJ296  SJ376  SJ212  SJ925  SJ17  SJ617  SJ917  SJ625  SJ723  SJ970 
Article reSeArcH
highlighting putative subgroup-specific origins. Our analyses also define the cellular states underlying each MB subgroup, disentangling determinants of intra-and intertumoral heterogeneity. These findings will enable future studies to assess translational opportunities and to evaluate the impact of therapeutic approaches on the spectrum of cellular states that drive MB.
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Methods
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Tissue sample collection and dissection. Human primary tumours. Patients and their parents at Boston Children's Hospital, the Medical University of Vienna and St Jude Children's Research Hospital gave consent preoperatively according to Institutional Review Board guidelines. Fresh tumours were collected at the time of surgery and processed directly. Tumour samples from Boston Children's Hospital and the Medical University of Vienna were mechanically and enzymatically dissociated using a papain-based brain tumour dissociation kit (Miltenyi Biotec). Tumour samples from St Jude Children's Research Hospital were pre-cut and dissociated for 30 min at 37 °C in papain solution (10 units/ml, Worthington, LS003126) containing N-acetyl-l-cysteine (160 μg/ml, Sigma-Aldrich, A9165) and DNase I (12 μg/ml, Sigma-Aldrich, DN25), rinsed in Neurobasal medium (Gibco, 21103049) supplemented with B-27 (Gibco, 17504044), N-2 (Gibco, 17502048) and l-glutamine (Gibco, 10378016), and filtered using a 40-μm strainer. Mouse cerebellum. Mouse cerebellar tissue from Crl:CD1 (ICR) mice at 13 distinct developmental time points was previously isolated 21 . Embryonic time points include each day between E10 to E18 and postnatal time points include P0, P4, P7, and P10. Two biological replicates were included at each time point and three at E14. Cerebella were dissociated as previously described. Single cells were sorted into 96-well plates containing cold TCL buffer (Qiagen, 1031576) containing 1% β-mercaptoethanol, snap frozen on dry ice, and then stored at −80 °C before whole-transcriptome amplification, library preparation and sequencing. Generation and processing of DNA methylation data. All single-cell patient and PDX samples were analysed using Illumina Infinium Methylation EPIC BeadChip arrays according to the manufacturer's instructions. Data were generated from both freshly frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. Medulloblastoma subgroup predictions were obtained from a web-platform for DNA methylation-based classification of central nervous system tumours (www. molecularneuropathology.org, version 11b4 35 ). Resulting assignment of samples to WNT, SHH, Group 3 and Group 4 subgroups were used for all downstream analyses. A similar classification system was used for predicting medulloblastoma subtypes 32 . CNV analysis from EPIC methylation array data was performed using the conumee Bioconductor package. Identified CNVs were compared to those predicted from the single-cell data (shown in Extended Data Fig. 2) . Generation of whole-exome and whole-genome sequencing data. Human genomic whole-exome sequencing libraries were generated using the SureSelect XT kit specific for the Illumina HiSeq instrument (Agilent Technologies), followed by exome enrichment using the SureSelect XT Human All Exon V5 without UTRs bait set. The resulting exome-enriched libraries of tumour and normal samples were then sequenced using paired-end 100-cycle sequencing on a NovaSeq 6000 (Illumina) according to the manufacturer's instructions. Whole-genome sequencing libraries were constructed using the TruSeq DNA PCR-free sample preparation kit according to the manufacturer's instructions. Tumour and normal samples were sequenced on an Illumina HiSeq 2500 instrument as previously described 36 . Somatic SNVs and INDELs were determined via the Mutect2 algorithm as implemented in GATK v.4.0. Coding and splice-related variants were subsequently annotated using the Medal Ceremony annotation pipeline. Additionally, all reported somatic variants were manually curated in IGV. Human scRNA-seq data generation and processing. Whole-transcriptome amplification, library construction and sequencing were performed as previously described following the Smart-seq2 modified protocol 13 . Expression levels were quantified as E i,j = log 2 (TPM i,j /10 + 1), where TPM i,j refers to transcript-permillion for gene i in sample j, as calculated by RSEM 37 . TPM values were divided by 10 as we estimated that the complexity of single-cell libraries was in the order of 100,000 transcripts and would like to avoid counting each transcript ~10 times, as would be the case with TPM, which may inflate the difference between the expression level of a gene in cells in which the gene is detected and those in which it is not detected.
To filter out low-quality cells, we first removed cells for which less than 2,500 genes were detected. For each processed 96-well plate, we then determined the average number of genes detected per cell minus two times its standard deviation. We then additionally filtered out the cells that were below that threshold. For the remaining cells, we calculated the aggregate expression of each gene as E a (i) = log 2 (average(TPM i,1...n ) + 1), and excluded genes with E a <4. In each subgroup (WNT, SHH, and Group 3/4), we defined relative expression by centering the expression levels, Er i,j = E i,j − average[E i,1...n ] for the remaining cells and genes. On average, we detected ~4,500 genes per cell. Gene expression values were uploaded to the Gene Expression Omnibus (accession number GSE119926).
Pearson correlation coefficients between expression profiles of cells that passed quality filtering was calculated using centred gene expression levels (for each subgroup separately, shown in Figs. 2a, 3a, 4a ). Cells were ordered by hierarchical clustering using 1 − correlation coefficient as the distance and Ward's linkage, within each sample or genetic subclone (for samples SJ99 and BCH825). Identification of CNVs in single-cell data. CNVs were estimated as previously described 13 by applying a moving average to the relative expression, with a sliding window of 100 genes within each chromosome after sorting genes by their chromosomal location (shown in Extended Data Fig. 2 ). Non-malignant tumour cells were determined by unsupervised clustering of all single-cell-derived copy-number profiles for each sample with 190 copy-number profiles derived from two nonmalignant cell types (tumour-associated oligodendrocytes and immune cells 14 ). For the majority of tumours (21/25), most of the cells did not cluster with the non-malignant cells but formed their own cluster(s) and showed clear evidence of CNVs. A small fraction of tumour cells clustered with the non-malignant cells (<4%). Given the high percentage of malignant cells in these tumours, we decided to classify all cells from the remaining four tumours (MUV41, SJ577, MUV34, and SJ625) as malignant. For two samples (SJ99 and BCH825) genetic subclones were identified based on their CNV profiles. Identification of SNVs in single-cell data. To detect mutant transcripts in our full-length scRNA-seq expression data (shown in Fig. 2c and Extended Data Fig. 3c-f) , sequencing reads were first aligned to the human genome build hg19 using STAR v.2.5.1b. RefSeq gene annotations were supplied to guide alignment. Variants were then quantified in each single cell at the genomic position at which they were detected in the whole-genome/whole-exome sequencing data using samtools mpileup v.1.3. For some genes multiple variants were detected (for example, four different variants were detected for CTNNB1 in WNT MB) and quantified separately. To detect mutant and wild-type transcripts, we required one or more supporting reads. We then filtered variants that were detected as mutant in less than three cells, or that were considered erroneously called as they were detected at elevated frequency in samples in which they were not detected in the genome sequencing data. A total of 82 variants remained after this filtering step. Mutations in highly expressed transcripts were detected in the majority of cells from the respective sample (for example, OTX2 Q103R mutation in MUV39). Mutations in less highly expressed transcripts were detected less frequently. Only a small number of mutant transcripts were detected in samples in which they were not detected by genome sequencing (for example, only ten mutant transcripts were detected for the respective other CTNNB1 variants in the WNT MB single cells; Fig. 2c ), illustrating the high specificity of our approach.
Identification of intratumour NMF programs and cellular hierarchies.
Transcriptional programs were determined as previously described 14 by applying NMF to the centred expression data 38 . Negative values were converted to zero. Analysis was performed for each sample and subclone individually (excluding samples for which less than 100 cells were profiled), using only the malignant cells and setting the number of factors to four for WNT and three for SHH and Group 3/4 tumours. For each of the resulting factors, we considered the 30 genes with the highest NMF scores to be characteristic of that factor (provided in Supplementary Data  Figs. 5a, 6a, 8a) . Hierarchical clustering, with one minus Pearson correlation as the distance metric and Ward's linkage, of the scores for each program revealed four (WNT subgroup) or three (SHH and Group 3/4 subgroups) main correlated sets of programs. The 30 genes with the highest average NMF score within each correlated program set (excluding ribosomal protein genes) were then used to define a total of ten subgroup-specific metaprograms (provided in Supplementary Table 2b) .
To interpret the characteristics of each metaprogram, we manually inspected their underlying gene signatures. Additionally, we tested for enrichment of described gene sets (GO biological processes cell cycle and neuron differentiation, KEGG hedgehog signalling pathway, and manually curated ribosomal proteins and translational initiation-elongation factors) in each metaprogram using Fisher's exact test. Generation of single-cell program expression scores. Single-cell expression scores were generated in a similar way as described previously 13 . Given a set of genes (G j ) reflecting a NMF program or metaprogram, we calculate for each cell i, a score, SC j (i), quantifying the relative expression of G j in cell i, as the average relative expression (Er) of the genes in G j , compared to the average relative expression of a control gene set G j
. The control gene set contains 100 genes with the most similar aggregate expression level. In this way, the control gene set has a comparable distribution of expression levels to that of the considered gene set, and the control gene set is 100-fold larger, such that its average expression is analogous to averaging over 100 randomly selected gene sets of the same size as the considered gene set.
Single cells were assigned to different cell populations based on the maximum expression score for their respective subgroup-specific metaprograms, excluding the cycling programs. The fraction of cells per tumour sample assigned to each cell population is provided in Supplementary Table 2d . Scores for the cycling programs were binarized into cycling and non-cycling (larger and smaller than 1, respectively). For illustration of the cellular hierarchies in SHH MB, scores were normalized by minimizing the average minimum difference of all cells per sample to −1 or 1 (shown in Fig. 3c ). For the pan-subgroup analysis of all malignant medulloblastoma cells we re-centred expression values across the dataset and calculated expression scores for each of the ten metaprograms. The pairwise correlation of expression scores is shown in Fig. 6a . Determination of cell population-specific genes. For comparison of cell populations in WNT tumours, we calculated the average expression level of all cells per population (log 2 -transformed, un-centred expression levels were used). For this analysis we excluded cells from BCH807, as it was very different from the other four WNT MBs and represents an atypical case (without cells scoring highest for the WNT-B metaprogram, highly proliferative, negative staining for nuclear β-catenin and lacking monosomy of chromosome 6). We then determined all genes with a difference smaller or larger than 1 between the average log 2 -transformed expression levels when comparing the undifferentiated proliferative population (highest for metaprogram WNT-B) against the neuron-like population (WNT-C) or undifferentiated post-mitotic population (WNT-D). A total of 640 genes were identified in this way (provided in Supplementary Table 2c, Extended Data Fig. 5c ).
For comparison of neuron-like cell populations between medulloblastoma subgroups, we first determined genes that were specific to any of the neuron-like populations. For every subgroup (WNT, SHH and Group 3/4), the average expression level of all neuron-like cells was compared to the average expression level of all undifferentiated cells from each subgroup, determining genes with a difference larger than 1 between the average log 2 -tranformed expression levels. This way we determined a total of 260 genes that were specific to the neuron-like cell population of at least one subgroup (provided in Supplementary Table 3 ). Genes that were specific to two or three subgroups were grouped as shared genes (Fig. 6c,  Extended Data Fig. 9e ). RNA in situ hybridization. Paraffin-embedded tissue sections from two WNT MB tumours of the single-cell cohort (SJ99 and SJ129) were obtained from St Jude Children's Research Hospital. Sections were mounted on glass slides and stored at −80 °C. Slides were stained using the RNAscope 2.5 HD Duplex Detection Kit (Advanced Cell Diagnostics (ACD), 322430). Slides were baked for 1 h at 60 °C, deparaffinized and dehydrated with xylene and ethanol. The tissue was pretreated with RNAscope Hydrogen Peroxide (ACD, 322335) for 10 min at room temperature and RNAscope Target Retrieval Reagent (ACD, 322000) for 15 min at 98 °C. RNAscope Protease Plus (ACD, 322331) was then applied to the tissue for 30 min at 40 °C. Hybridization probes were prepared by diluting the C2 probe (red) 1:50 into the C1 probe (green). Advanced Cell Technologies RNAscope Target Probes used included Hs-MKI67 (ACD, 591771 and 591771-C2), Hs-DKK2 (ACD, 531131-C2), Hs-STMN2 (ACD, 525211-C2), Hs-ZFP36 (ACD, 427351) and Hs-EGR1 (ACD, 457671). Probes were added to the tissue and hybridized for 2 h at 40 °C. A series of ten amplification steps were performed using instructions and reagents provided in the RNAscope 2.5 HD Duplex Detection Kit. Tissue was counterstained with Gill's haematoxylin for 25 s at room temperature followed by mounting with VectaMount mounting media (Vector Laboratories). Immunohistochemistry. Double labelling immunohistochemistry was performed using a 1:8,000 dilution of anti-tubulin β3 (clone TUJ1, Biolegend) and 1:25 dilution of anti-MYC (clone Y69, Abcam) diluted in Ventana antibody diluent (Roche Tissue Diagnostic, 251-018) and detected using the UltraView Red (Roche Tissue Diagnostics, 760-501) and UltraView DAB (Roche Tissue Diagnostics, 760-500) detection kits, respectively. Each target was evaluated using a semiquantitative system to construct a H-score, obtained by multiplying the intensity of the stain (0: no staining; 1: weak staining; 2: moderate staining, and 3: strong staining) by the percentage (0 to 100) of cells showing that staining intensity (H-score range, 0 to 300). Mouse scRNA-seq data generation and processing. Single cells from developing mouse cerebellar tissue were processed using the microfluidics-based 10x Chromium protocol, as previously described 21 . In brief, single cells were prepared using the Chromium v.1 Single Cell 3′ Library and Gel Bead Kit according to the manufacturers' specifications. Quantification and quality checks for the library were performed using an Agilent Technologies DNA 1000 chip. Libraries were sequenced on an Illumina HiSeq 2500 machine. Raw sequencing data have been uploaded to the European Nucleotide Archive (accession PRJEB23051).
Mouse developing cerebellum cells were filtered and normalized using the scanpy Python package 39 . Genes expressed in less than 50 cells and cells expressing less than 200 genes were removed. Additionally, cells with less than 524 and greater than 3,206 total counts (±3 median absolute deviations) were removed. Furthermore, those cells with greater than 5% of their total counts mapping to mitochondrial genes were removed. Gene expression values were then divided by the total number of transcripts and multiplied by 10,000. Normalized values were calculated by natural-log transforming these values. We calculated scaled expression (z scores for each gene) for downstream analysis. Identification of cell types in developing mouse cerebellum. The scanpy package implemented in Python was applied to identify cell types among 82,228 cells expressing a total of 16,475 genes. After two rounds of clustering (using the Louvain method), populations predicted to be of non-cerebellar origins were excluded. Removed populations were enriched for haemoglobin, oligodendrocycte, and/or immune associated genes. The remaining 78,156 cells were visualized by t-SNE (using the first 100 principle components as input) and clustered a third time. We then merged clusters if the Mantel Spearman correlation between gene distance matrices (using Manhattan distance) was greater than 0.9 (Fig. 1c, Extended Data  Fig. 4c ). Resulting clusters, in conjunction with marker genes, were used to identify major cell types in the developing cerebellum. Integrated analysis of mouse and human datasets. Gene expression matrices for human and mouse datasets were restricted to the 16,919 high-confidence homologous genes with gene order conservation and whole-genome alignment scores greater than 75%, as defined by Ensembl. We removed genes without expression in at least 200 cells and filtered out those with gene dispersion across cells/samples less than equal to zero in each dataset. We also regressed out individual-specific effects in the single-cell data.
For CCA, the first 30 canonical correlation vectors were calculated to project each expression matrix into the maximally correlated subspace, as similarly described previously 40 . In brief, CCA is implemented as singular value decomposition, by implicitly restarted Lanczos bidiagonalization algorithm, of a distance matrix between two gene expression matrices.
We adopted a correlation of differential expression approach to measure similarity between biological groups in two different studies. Such a procedure has previously been shown to be effective in implicating cellular origins for WNT and SHH medulloblastoma subgroups 41 . Gene expression for each cell, or centroids for each cluster when at the cluster level, is subtracted by mean gene expression of all other cluster centroids to determine differential expression. Cosine distance is then used to calculate correlations between differential expression vectors between studies as a metric for similarity (Figs. 1d, 3d, e, Extended Data Figs. 4f, 7j, 10a , f). Significance is assessed by 10,000 permutations, followed by FDR correction, for cluster labels of interest. Genes driving CCA differential correlations between human and mouse datasets were investigated by identifying genes both differentially expressed in the cell type of interest (Mann-Whitney U-test) and correlated with the CCA correlation (Pearson correlation). Significant genes were those predicted to drive CCA differential correlations.
NMF applied to the centred mouse expression data, with negative values assigned to zero and rank set to two, determined an undifferentiated and differentiated program. Both programs were projected onto a centred dataset of interest, scaled to a range of zero and one, then differentiated programs were subtracted from undifferentiated programs to calculate differentiation scores 42 (shown in Extended Data Fig. 4b) . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Single cell sequencing data was generated using the Illumina NextSeq 500 system according to the manufacturer's instructions. DNA methylation data was generated using Illumina Infinium MethylationEPIC arrays according to the manufacturer's instructions. Human genomic libraries were generated using the SureSelectXT kit specific for the Illumina HiSeq instrument, followed by exome enrichment using the SureSelectXT Human All Exon V5 without UTRs bait set. The resulting exome enriched libraries were then sequenced using paired end 100 cycle sequencing on a NovaSeq 6000 (Illumina) according to manufacturer's instructions.
To analyze data we used publicly available open-source software (RSEM, Bowtie, Samtools, GATK). Further analysis was performed using R and Python programming languages and several publicly available packages (NMF, conumee).
Data presented in this manuscript has been uploaded to GEO (GSE119926; tumor data) and to ENA (PRJEB23051; mouse cerebellum data).
